PharmaNutra SpAFRA:761 +1.40%95 Net Margin % is 10.36% as of Mar. 2026, which is 35% below its 10-year median of 15.83. GuruFocus rates FRA:761 with a GF Score™ of 95/100 and a GF Value™ of €67.96 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, PharmaNutra SpA ranks better than 79.08% on this metric.
Net margin is calculated as Net Income divided by its Revenue. PharmaNutra SpA's Net Income for the
three
months ended in Mar. 2026 was €3.5 Mil. PharmaNutra SpA's Revenue for the
three
months ended in Mar. 2026 was €33.3 Mil. Therefore, PharmaNutra SpA's net margin for the quarter that ended in Mar. 2026 was 10.36%.
The historical rank and industry rank for PharmaNutra SpA's Net Margin % or its related term are showing as below:
FRA:761'
s Net Margin % Range Over the Past 10 Years
Min: 11.75 Med: 15.83 Max: 24.06
Current: 15.06
FRA:761's Net Margin % is ranked better than 79.08% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs FRA:761: 15.06
PharmaNutra SpA (FRA:761) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
PharmaNutra SpA Net Margin % Related Terms
PharmaNutra SpA Net Margin % Historical Data
* Premium members only.
The historical data trend for PharmaNutra SpA's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:761 vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaNutra SpA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaNutra SpA Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaNutra SpA's Net Margin % distribution charts can be found below:
* The bar in red indicates where PharmaNutra SpA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaNutra SpA (FRA:761) has a Net Margin % of 10.36% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on PharmaNutra SpA and its competitors. This is 35% below median its historical median of 15.83. Over the past decade, PharmaNutra SpA's Net Margin % has ranged from 11.75 to 24.06. According to the industry distribution chart, PharmaNutra SpA ranks #200 out of 956 companies in the Drug Manufacturers industry, placing it in the top 20.9%.
Is PharmaNutra SpA's Net Margin % too high?
PharmaNutra SpA's current Net Margin % of 10.36% is 35% below median its 10-year median of 15.83. Over the past 10 years, this metric has ranged from a low of 11.75 to a high of 24.06. The Drug Manufacturers industry median Net Margin % is 5.56. PharmaNutra SpA's value of 10.36% is 86.3% above this industry median. Based on the distribution chart, PharmaNutra SpA ranks #200 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaNutra SpA has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmaNutra SpA's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaNutra SpA ranks #200 out of 956 companies for Net Margin %. This places PharmaNutra SpA in the top 21% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. PharmaNutra SpA's value of 10.36% is 86.3% above this benchmark. Historically, PharmaNutra SpA's own Net Margin % has ranged from 11.75 to 24.06 over the past decade. While the company's 10-year median is 15.83 vs. the industry median of 5.56, PharmaNutra SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaNutra SpA's current Net Margin % of 10.36% is 86.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PharmaNutra SpA and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaNutra SpA's current Net Margin % is 10.36%, which is 35% below median its own 10-year median of 15.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaNutra SpA stock overvalued right now?
Based on GuruFocus' analysis, PharmaNutra SpA (FRA:761) is currently considered Modestly Overvalued. The stock's GF Value™ is €67.96, compared to a current price of €86.70 — trading 27.6% above its estimated fair value. The current Net Margin % is 10.36%, which is 35% below median its 10-year median of 15.83 and 86.3% above the Drug Manufacturers industry median of 5.56. PharmaNutra SpA's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For PharmaNutra SpA (FRA:761), the current Net Margin % is 10.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaNutra SpA (FRA:761) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaNutra SpA stock appears to be overvalued.
The current stock price of €86.70 is trading 27.6% above its estimated GF Value™ of €67.96.
GuruFocus considers PharmaNutra SpA to be Modestly Overvalued.
Key valuation signals for FRA:761:
Net Margin %: 10.36% (35% below median its 10-year median of 15.83)
GF Value™: €67.96 vs. price of €86.70 (27.6% above fair value)
Industry Position: 86.3% above the Drug Manufacturers median (#200 of 956)
No single metric tells the full story. See the FRA:761 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, and other regions.
95GF Score
Get the complete analysis for FRA:761
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:761 has been successfully added to your 
